

## Technology Advisory Committee B Interests Register

**Topic: Bulevirtide for treating chronic hepatitis D [ID3732]**

**Publication Date: 07/06/2023**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Mark Aldersley	Clinical expert	Indirect financial interest	Has received lecture fees from Gilead for non-promotional meetings relating to Hepatitis C and D.		13/10/22		It was agreed that this declaration would not prevent Dr Aldersley from providing expert advice to the committee.
Professor Will Irving	Clinical expert	Indirect financial interests	Due to being the lead investigator on a sponsored research grant from Gilead Sciences entitled "The epidemiology of HDV infection in the UK", having participated in an Advisory Board for Gilead Sciences on HDV infection in 2021, and being an independent referee for Gilead research fellowship schemes.		23/02/22		It was agreed these declarations would not prevent Professor Irving from providing expert advice to the committee.